-
1
-
-
79951575730
-
-
American Cancer Society 2010
-
Cancer Facts and Figures (2010) American Cancer Society 2010
-
(2010)
Cancer Facts and Figures
-
-
-
2
-
-
79952945610
-
-
Surveillance Epidemiology and End Results (SEER) (Accessed April 14, 2011)
-
Surveillance Epidemiology and End Results (SEER). SEER Stat Fact Sheet: Pancreas. Available at http://www.seer. cancer.gov/statfacts/html/pancreas.html (Accessed April 14, 2011)
-
SEER Stat Fact Sheet: Pancreas
-
-
-
3
-
-
0027198603
-
Pancreatic cancer: How can we progress?
-
Casper ES (1993) Pancreatic cancer: how can we progress? Eur J Cancer 29A(2):171-172
-
(1993)
Eur J Cancer
, vol.29 A
, Issue.2
, pp. 171-172
-
-
Casper, E.S.1
-
4
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403-2413
-
(1997)
J Clin Oncol
, vol.15
, Issue.6
, pp. 2403-2413
-
-
Burris Iii, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
-
5
-
-
0036682041
-
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
-
Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20(15):3270-3275
-
(2002)
J Clin Oncol
, vol.20
, Issue.15
, pp. 3270-3275
-
-
Berlin, J.D.1
Catalano, P.2
Thomas, J.P.3
Kugler, J.W.4
Haller, D.G.5
Benson Iii, A.B.6
-
6
-
-
0037100983
-
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
-
Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87 (2):161-167
-
(2002)
Br J Cancer
, vol.87
, Issue.2
, pp. 161-167
-
-
Bramhall, S.R.1
Schulz, J.2
Nemunaitis, J.3
Brown, P.D.4
Baillet, M.5
Buckels, J.A.6
-
7
-
-
0037083621
-
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale
-
Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G et al (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94(4):902-910
-
(2002)
Cancer
, vol.94
, Issue.4
, pp. 902-910
-
-
Colucci, G.1
Giuliani, F.2
Gebbia, V.3
Biglietto, M.4
Rabitti, P.5
Uomo, G.6
-
8
-
-
0141688333
-
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
-
Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A et al (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21(17):3296-3302
-
(2003)
J Clin Oncol
, vol.21
, Issue.17
, pp. 3296-3302
-
-
Moore, M.J.1
Hamm, J.2
Dancey, J.3
Eisenberg, P.D.4
Dagenais, M.5
Fields, A.6
-
9
-
-
2342645506
-
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
-
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22(8):1430-1438
-
(2004)
J Clin Oncol
, vol.22
, Issue.8
, pp. 1430-1438
-
-
Van Cutsem, E.1
Van De Velde, H.2
Karasek, P.3
Oettle, H.4
Vervenne, W.L.5
Szawlowski, A.6
-
10
-
-
79955921754
-
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
-
Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. NEJM 364 (19):1817-1825
-
(2011)
NEJM
, vol.364
, Issue.19
, pp. 1817-1825
-
-
Conroy, T.1
Desseigne, F.2
Ychou, M.3
-
11
-
-
84866735224
-
-
Investigational Brochure: Ro 31-7453.: Nutley, NJ. Hoffmann-La Roche, Inc. 1999
-
Investigational Brochure: Ro 31-7453.: Nutley, NJ. Hoffmann-La Roche, Inc. 1999
-
-
-
-
12
-
-
3042851771
-
A phase i clinical and pharmacokinetic study of Ro 31-7453 given as a 7-or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors
-
Salazar R, Bissett D, Twelves C, Breimer L, DeMario M, Campbell S et al (2004) A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7-or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors. Clin Cancer Res 10(13):4374-4382
-
(2004)
Clin Cancer Res
, vol.10
, Issue.13
, pp. 4374-4382
-
-
Salazar, R.1
Bissett, D.2
Twelves, C.3
Breimer, L.4
Demario, M.5
Campbell, S.6
-
13
-
-
4344601239
-
Phase i and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors
-
Dupont J, Bienvenu B, Aghajanian C, Pezzulli S, Sabbatini P, Vongphrachanh P et al (2004) Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors. J Clin Oncol 22 (16):3366-3374
-
(2004)
J Clin Oncol
, vol.22
, Issue.16
, pp. 3366-3374
-
-
Dupont, J.1
Bienvenu, B.2
Aghajanian, C.3
Pezzulli, S.4
Sabbatini, P.5
Vongphrachanh, P.6
-
14
-
-
84866740412
-
Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC)
-
suppl;abstr 19005
-
Hanna NH EJ, Arnott J et al (2009) Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 27: suppl;abstr 19005
-
(2009)
J Clin Oncol
, vol.27
-
-
Hanna, N.H.E.J.1
Arnott, J.2
-
15
-
-
67649649913
-
Phase 2 study of MKC-1 in patients with metastatic breast cancer who have failed prior therapy with an anthracycline and taxane
-
suppl;abstr 11508
-
Sylvester L LL, Jabboury J et al (2007) Phase 2 study of MKC-1 in patients with metastatic breast cancer who have failed prior therapy with an anthracycline and taxane. J Clin Oncol 25(18S): suppl;abstr 11508
-
(2007)
J Clin Oncol
, vol.25
, Issue.18 S
-
-
Sylvester, L.L.L.1
Jabboury, J.2
-
16
-
-
74249089222
-
Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer
-
suppl;abstr 5577
-
Elser C HH, Kaizer H et al (2009) Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer. J Clin Oncol 27(15s):suppl;abstr 5577
-
(2009)
J Clin Oncol
, vol.27
, Issue.15 S
-
-
Elser, C.H.H.1
Kaizer, H.2
-
17
-
-
84864337846
-
Phase i study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design
-
doi:10.1007/s10637-010-9629-6
-
Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J et al (2011) Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. doi:10.1007/s10637- 010-9629-6
-
(2011)
Invest New Drugs
-
-
Tevaarwerk, A.1
Wilding, G.2
Eickhoff, J.3
Chappell, R.4
Sidor, C.5
Arnott, J.6
|